Simcere Pharmaceutical Sustainability Profile
Simcere Pharmaceutical Group, commonly known as Simcere, is a leading biopharmaceutical company headquartered in Nanjing, China. Founded in 1995, Simcere has established a strong presence in the pharmaceutical industry, focusing on the research, development, manufacturing, and marketing of innovative medicines. The company primarily operates in oncology, central nervous system disorders, and autoimmune diseases, with a commitment to enhancing patient outcomes through advanced therapeutics. With a robust portfolio of core products, including proprietary drugs and biosimilars, Simcere distinguishes itself through its dedication to quality and innovation. The company has achieved significant milestones, including successful collaborations and a growing international footprint, positioning itself as a key player in the global pharmaceutical market. Simcere's ongoing efforts in research and development underscore its commitment to addressing unmet medical needs and improving healthcare worldwide.
DitchCarbon Score
How does Simcere Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Simcere Pharmaceutical's score of 29 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Simcere Pharmaceutical's reported carbon emissions
In 2023, Simcere Pharmaceutical, headquartered in China (CN), reported total carbon emissions of approximately 3,146,740 kg CO2e. This figure includes 73,490 kg CO2e from Scope 1 emissions, 2,001,370 kg CO2e from Scope 2 emissions, and 1,071,880 kg CO2e from Scope 3 emissions. Comparatively, in 2022, the company emitted about 1,915,640 kg CO2e, with Scope 1 emissions at 38,940 kg CO2e, Scope 2 at 1,296,120 kg CO2e, and Scope 3 at 580,580 kg CO2e. This indicates a significant increase in total emissions year-on-year, reflecting a rise from 2,616,670 kg CO2e in 2021 and 67,184,370 kg CO2e in 2020, where Scope 1 and 2 emissions were notably high at 4,819,360 kg CO2e and 62,365,010 kg CO2e, respectively. Despite the increase in emissions, Simcere Pharmaceutical has not publicly disclosed specific reduction targets or initiatives as part of their climate commitments. The company does not appear to have cascaded any emissions data from a parent organization, and there are no reported commitments to initiatives such as the Science Based Targets initiative (SBTi) or other climate pledges. Overall, while Simcere Pharmaceutical has made strides in emissions reporting, the lack of reduction targets suggests an opportunity for enhanced climate action and commitment to sustainability in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 4,819,360 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 62,365,010 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 0,000,000 | 000,000 | 0,000,000 |
How Carbon Intensive is Simcere Pharmaceutical's Industry?
How Carbon Intensive is Simcere Pharmaceutical's Location?
Simcere Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Simcere Pharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
